Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 5/20 | 0.64 |
| ▸ | WNT3A | P56704 | 5/20 | 0.64 |
| ▸ | FLT3 | P36888 | 2/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.61 |
| ▸ | CDK2 | P24941 | 1/20 | 0.61 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.60 |
| ▸ | STAT3 | P40763 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.51 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29444537 | 0.85 | FLT3 (0.65) | CTNNB1WNT3AFLT3CCNA2CDK2 | |
| SCHEMBL42245 | 0.85 | FLT3 (0.65) | CTNNB1WNT3AFLT3CCNA2CDK2 | |
| Potassium Ion SCHEMBL2688939 | 0.84 | KDM4E (0.63) | CTNNB1WNT3AFLT3CCNA2CDK2 | |
| SCHEMBL1762971 | 0.84 | KDM4E (0.58) | CTNNB1WNT3AFLT3CCNA2CDK2 | |
| Hydrochloric Acid SCHEMBL4258298 | 0.83 | FLT3 (0.63) | CTNNB1WNT3AFLT3CCNA2CDK2 | |
| SCHEMBL27541852 | 0.83 | FLT3 (0.63) | CTNNB1WNT3AFLT3CCNA2CDK2 | |
| SCHEMBL7668372 | 0.82 | KDM4E (0.66) | CTNNB1WNT3AFLT3CCNA2CDK2 | |
| SCHEMBL31148407 | 0.82 | KDM4E (0.66) | CTNNB1WNT3AFLT3CCNA2CDK2 | |
| Oxalic Acid SCHEMBL6033591 | 0.82 | FLT3 (0.58) | CTNNB1WNT3AFLT3CCNA2CDK2 | |
| Hydrazine SCHEMBL27690059 | 0.81 | FLT3 (0.61) | CTNNB1WNT3AFLT3CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513832-B1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | BRISTOL MYERS SQUIBB CO (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-1575493-B1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC SULFONYLUREIDO PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8039486-B2 | Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1638568-B1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2011-07-27 | — | — | EP | disclosed |
| US-7915283-B2 | e.g. 1-[4-(1-Phenyl-1-(pyrazinyl)-methylene)-piperidin-1-yl]-2-(4-methoxy-7-pyrazinyl-6-azaindol-3-yl)-ethane-1,2-dione; viricides for prophylaxis of lympadenopathy associated virus; synergystic mixtures with immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| WO-2008134036-A1 | ALPHA-SUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-α]PYRIMIDINE AMIDE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008134035-A1 | ALPHA-UNSUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-A] PYRIMIDINE AMIDE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080188481-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-07 | — | — | US | disclosed |
| EP-1638568-A4 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20050075364-A1 | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2005-04-07 | — | — | US | disclosed |
| EP-1513832-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | Bristol-Myers Squibb Company (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2005004801-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20040186292-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-09-23 | — | — | US | disclosed |
| WO-2004043337-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040063744-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-04-01 | — | — | US | disclosed |
| US-20040063746-A1 | Indole, azaindole and related heterocyclic ureido and thioureido piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004011425-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC UREIDO AND THIOUREIDO PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040006090-A1 | Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-01-08 | — | — | US | disclosed |
| WO-2004000210-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC SULFONYLUREIDO PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | THPO, DPYD, TPMT | CTNNB1 3067/4885WNT3A 4613/4885FLT3 767/4885 |
| US-20050075364-A1 | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives | IDO2, IDO1, INMT | CTNNB1 3262/4885WNT3A 3114/4885FLT3 2637/4885 |
| US-20040063744-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | IDO1, IDO2, INMT | CTNNB1 2501/4885WNT3A 1473/4885FLT3 2976/4885 |
| US-20080188481-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | IDO1, IDO2, INMT | CTNNB1 2665/4885WNT3A 1654/4885FLT3 2415/4885 |
| US-20040186292-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | IDO1, IDO2, INMT | CTNNB1 2501/4885WNT3A 1473/4885FLT3 2976/4885 |
| US-20040006090-A1 | Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives | IDO1, IDO2, INMT | CTNNB1 965/4885WNT3A 449/4885FLT3 3081/4885 |
| US-20040063746-A1 | Indole, azaindole and related heterocyclic ureido and thioureido piperazine derivatives | IDO1, IDO2, TPMT | CTNNB1 2703/4885WNT3A 851/4885FLT3 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.